Display options
Cite
Comella K, Parlo M, Daly R, et al. Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction. J Clin Med Res. 2017;9(11):935-942doi: 10.14740/jocmr3187w.
Comella, K., Parlo, M., Daly, R., Depasquale, V., Edgerton, E., Mallory, P., Schmidt, R., & Drake, W. P. (2017). Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction. Journal of clinical medicine research, 9(11), 935-942. https://doi.org/10.14740/jocmr3187w
Comella, Kristin, et al. "Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction." Journal of clinical medicine research vol. 9,11 (2017): 935-942. doi: https://doi.org/10.14740/jocmr3187w
Comella K, Parlo M, Daly R, Depasquale V, Edgerton E, Mallory P, Schmidt R, Drake WP. Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction. J Clin Med Res. 2017 Nov;9(11):935-942. doi: 10.14740/jocmr3187w. Epub 2017 Oct 02. PMID: 29038672; PMCID: PMC5633095.
Copy Download .nbib Format: NLM
Share it on

J Clin Med Res. 2017 Nov;9(11):935-942. doi: 10.14740/jocmr3187w. Epub 2017 Oct 02.

Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction.

Journal of clinical medicine research

Kristin Comella, Michelle Parlo, Rosemary Daly, Vincent Depasquale, Eric Edgerton, Patrick Mallory, Roy Schmidt, Walter P Drake

Affiliations

  1. US Stem Cell, Inc., 13794 NW 4th Street, Suite 212, Sunrise, FL 33325, USA.
  2. Panama College of Cell Science, 3rd Floor, C&H Towers Corner of Great Marlboro and Great George Streets Roseau, 00152, Commonwealth of Dominica.
  3. US Stem Cell Clinic, 12651 Sunrise Blvd, Suite 104, Sunrise, FL 33323, USA.
  4. NSI Stem Cell, 3118 Gulf to Bay Blvd, Suite 310, Clearwater, FL 33759, USA.
  5. Mallory Family Wellness, 1548 North Boise Ave., Loveland, CO 80538, USA.
  6. New Life Medical Group, 15 Stonebridge, Jackson, TN 38305, USA.

PMID: 29038672 PMCID: PMC5633095 DOI: 10.14740/jocmr3187w

Abstract

BACKGROUND: Stem cells from adipose tissue offer a novel therapy for patients with damaged tissue. Stromal vascular fraction (SVF) injected into patients may reduce inflammation, promote healing, and repair damaged/scarred tissue. SVF can be isolated from fat (adipose) tissue in an outpatient procedure. The SVF population includes mesenchymal stem cells (MSCs), pericytes, endothelial/progenitor cells, fibroblasts and growth factors where the adipocyte (fat cell) population has been removed. Here we describe the use of SVF in the clinic for degenerative diseases in orthopedics, neurological conditions and systemic conditions in 676 patients.

METHODS: This study demonstrated the strong safety profile from a multi-center analysis of SVF injection in treating various diseases. Approximately 60 mL of fat tissue was removed from the abdomen or flanks using a local tumescent liposuction procedure. The fat was separated via centrifuge to isolate the SVF and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into the same patient. All subjects were monitored for adverse events.

RESULTS: The procedure demonstrates exceptional patient safety, and the study underscores the safety of autologous stem cell therapy in general. Few adverse events were reported and were overwhelmingly of mild and transient nature, such as the expected soreness at the site of liposuction and occasional headache.

CONCLUSION: The three deaths reported were most likely not related to the treatment but instead to the underlying disease. Our study demonstrates a strong safety profile with low complication rates.

Keywords: Adipose tissue; Adipose-derived stromal/stem cells; Cell therapy; Mesenchymal stem cells; Platelet rich plasma; Regenerative medicine; Stem cells; Stromal vascular fraction

Conflict of interest statement

KC is an officer of US Stem Cell, Inc.

References

  1. Circulation. 2004 Mar 16;109(10):1292-8 - PubMed
  2. Cytotherapy. 2004;6(1):7-14 - PubMed
  3. Cell Stem Cell. 2011 Jul 8;9(1):11-5 - PubMed
  4. J Transl Med. 2017 Jan 13;15(1):12 - PubMed
  5. Circ Res. 2007 May 11;100(9):1249-60 - PubMed
  6. In Vitro Cell Dev Biol Anim. 2015 Feb;51(2):142-50 - PubMed
  7. Stem Cells Int. 2016;2016:5762916 - PubMed
  8. J Transl Med. 2017 Jun 19;15(1):141 - PubMed
  9. Ann Chir Plast Esthet. 2017 Dec;62(6):609-616 - PubMed
  10. J Clin Med Res. 2017 Aug;9(8):701-708 - PubMed
  11. J Transl Med. 2009 Apr 24;7:29 - PubMed
  12. Circ Res. 2008 Jan 4;102(1):77-85 - PubMed
  13. Adv Biochem Eng Biotechnol. 2013;129:59-71 - PubMed
  14. Knee Surg Sports Traumatol Arthrosc. 2017 Mar 1;:null - PubMed
  15. J Transl Med. 2016 Jun 02;14 (1):158 - PubMed
  16. Int Med Case Rep J. 2017 Aug 16;10 :295-299 - PubMed
  17. Methods Mol Biol. 2013;1036:207-12 - PubMed
  18. Curr Stem Cell Res Ther. 2013 Jul;8(4):270-7 - PubMed
  19. Curr Res Transl Med. 2017 Jan - Mar;65(1):40-43 - PubMed
  20. Aesthetic Plast Surg. 2015 Dec;39(6):833-46 - PubMed

Publication Types